Skip to content
akaturk Academic measurement

OpenAlex topic

Hemoglobin structure and function

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 673 works 5 author topics

Works

673 works

  1. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 92.6%

    Vibrational dynamics of folded proteins is studied using a Gaussian model in which the protein is viewed as a network, residues representing the junctions, and the connectivity being established by a single parameter harmonic potential. Application to seven proteins showed that the local packing density plays a major…

  2. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    Erythropoietin (EPO) is both hematopoietic and tissue protective, putatively through interaction with different receptors. We generated receptor subtype-selective ligands allowing the separation of EPO's bioactivities at the cellular level and in animals. Carbamylated EPO (CEPO) or certain EPO mutants did not bind to…

  3. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.9%

    Plasma xanthine oxidase (XO) activity was defined as a source of enhanced vascular superoxide (O \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \setlength{\oddsidemargin}{-69pt} \begin{document} \begin{equatio…

  4. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.5%

    Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance by developing chemoresistant TNBC tumors in vivo and characterizing their transcriptomes by RN…

  5. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.5%

    Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance by developing chemoresistant TNBC tumors in vivo and characterizing their transcriptomes by RN…

  6. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.5%

    Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance by developing chemoresistant TNBC tumors in vivo and characterizing their transcriptomes by RN…

  7. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.5%

    Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance by developing chemoresistant TNBC tumors in vivo and characterizing their transcriptomes by RN…

  8. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.5%

    Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance by developing chemoresistant TNBC tumors in vivo and characterizing their transcriptomes by RN…

  9. OpenAlex top 10% OpenAlex 94.9%

    Human serum albumin, a negative acute phase reactant and marker of nutritive status, presents at high concentrations in plasma. Albumin has always been used in many clinical states especially to improve circulatory failure. It has been showed that albumin is involved in many bioactive functions such as regulation of p…

  10. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 97.8%

    The intermittent vascular occlusion occurring in sickle cell disease (SCD) leads to ischemia-reperfusion injury and activation of inflammatory processes including enhanced production of reactive oxygen species and increased expression of inducible nitric-oxide synthase (NOS2). Appreciating that impaired nitric oxide-d…

  11. YÖKSİS SJR Q2 JCR Q1 OpenAlex 85.0%

    No abstract yet.

  12. YÖKSİS SJR Q2 JCR Q1 OpenAlex top 10% OpenAlex 95.5%

    No abstract yet.

Academicians

5 academicians